MiSeq – one of the most universal NGS platforms. Access focused applications such as targeted resequencing, metagenomics, small genome sequencing, targeted gene expression profiling, and more. MiSeq reagents enable up to 15 Gb of output with 25 million sequencing reads and 2 × 300 bp read lengths.
The MiSeqDx instrument is the first Food and Drug Administration (FDA)-regulated and Conformite Europeene in vitro diagnostic (CE-IVD)-marked platform for NGS.
The NextSeq 550 System delivers the power of high-throughput sequencing with the speed, simplicity, and affordability of a benchtop next-generation sequencing (NGS) system. The NextSeq 550 System fits into research laboratories, without need for specialized equipment. Perform many combinations of high- and mid-throughput sequencing applications to advance your studies.
iSeq 100 is Affordable and Accessible Benchtop Sequencer. Leveraging the speed and affordability of complementary metal-oxide-semiconductor (CMOS) technology and the accuracy of sequencing by synthesis (SBS) chemistry, the iSeq 100 System enables virtually any lab to acquire powerful next-generation sequencing (NGS) technology.
The NextSeq 550Dx instrument is FDA regulated and CE-in vitro diagnostic (IVD) marked, enabling clinical laboratories to develop and perform a wide range of applications, from NGS IVD assays using targeted panels, to clinical research applications that include methods from targeted panels to whole genomes.
The MiniSeq System delivers the power and confidence of proven Illumina next-generation sequencing (NGS) technology in an accessible sequencing solution. It features cost-efficient sequencing, even for low numbers of samples. Its streamlined workflow enables rapid sequencing of both DNA and RNA. The small footprint allows it to fit seamlessly into laboratories, with no need for specialized, ancillary equipment.
The NovaSeq 6000 System providing users with the throughput, speed, and flexibility to complete projects faster and more economically than ever before. Applications requiring large amounts of data, such as human wholegenome sequencing (WGS), ultradeep exome sequencing, and tumor–normal profiling can now be completed in a more costeffective manner. The same instrument can be used for less data-intensive methods, such as targeted resequencing.